Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Large Decline in Short Interest
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) experienced a significant decline in short interest in May, with a decrease of 10.3% from the previous month. The company's stock has a short interest of 1.3% and a days-to-cover ratio of 2.0. The company's financial performance for the quarter showed a negative return on equity and a negative net margin. Analysts have issued various ratings on Werewolf Therapeutics.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 372,000 shares, a decline of 10.3% from the April 30th total of 414,500 shares. Currently, 1.3% of the company's stock are short sold. Based on an average daily volume of 185,300 shares, the days-to-cover ratio is currently 2.0 days.
Get Werewolf Therapeutics alerts:
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Financial Perspectives Inc lifted its position in Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company's stock worth $26,000 after acquiring an additional 3,000 shares during the last quarter. Certuity LLC acquired a new position in Werewolf Therapeutics during the 4th quarter worth $39,000. Lighthouse Investment Partners LLC acquired a new position in Werewolf Therapeutics during the 4th quarter worth $87,000. Denali Advisors LLC acquired a new position in Werewolf Therapeutics during the 1st quarter worth $172,000. Finally, Acadian Asset Management LLC lifted its position in Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company's stock worth $1,119,000 after acquiring an additional 94,212 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company's stock.
Werewolf Therapeutics Stock Down 22.8 %
NASDAQ:HOWL traded down $1.18 during trading hours on Monday, reaching $3.99. The company's stock had a trading volume of 409,564 shares, compared to its average volume of 224,620. The company has a market cap of $173.41 million, a price-to-earnings ratio of -4.00 and a beta of 0.62. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19. The business's 50-day moving average is $5.62 and its 200-day moving average is $5.06. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.71 and a quick ratio of 6.71.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. Equities research analysts predict that Werewolf Therapeutics will post -1.52 EPS for the current year.
Analyst Ratings Changes
Several analysts have issued reports on HOWL shares. Wedbush reissued an "outperform" rating and set a $9.00 target price on shares of Werewolf Therapeutics in a research note on Monday, May 6th. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Monday. Finally, JMP Securities restated a "market outperform" rating and set a $12.00 price target on shares of Werewolf Therapeutics in a report on Monday, May 6th.
View Our Latest Analysis on Werewolf Therapeutics
Werewolf Therapeutics Company Profile
(Get Free Report)Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Read More
- Five stocks we like better than Werewolf Therapeutics
- How to Invest in Small Cap Stocks
- Why Smartsheet Stock is an Undervalued Gem of an Investment
- Stock Average Calculator
- The Most Upgraded Stocks After the Q1 Earnings Season
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- What Is Risk Tolerance & Why Is It Important?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Collapse of the Petrodollar (From Colonial Metals) (Ad)
Should you invest $1,000 in Werewolf Therapeutics right now?
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
